

# 1 **A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses** 2 **and hampers biomarker discovery**

3 Jeroen H.A. Creemers<sup>1,4</sup>, W. Joost Lesterhuis<sup>3</sup>, Niven Mehra<sup>2</sup>, Winald R. Gerritsen<sup>2</sup>,  
4 Carl G. Figdor<sup>1,4</sup>, I. Jolanda M. de Vries<sup>1</sup>, Johannes Textor<sup>1,5\*</sup>

- 5
- 6 1) Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences;  
7 Radboudumc, Nijmegen, The Netherlands
  - 8 2) Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
  - 9 3) School of Biomedical Sciences and Telethon Kids Institute, University of Western Australia,  
10 Perth, Australia
  - 11 4) Oncode Institute, Nijmegen, The Netherlands
  - 12 5) Data Science Department, Institute for Computing and Information Sciences, Radboud  
13 University, Nijmegen, The Netherlands
- 14

15 \* Corresponding author:

16 Dr. J. Textor

17 Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc,  
18 Geert Grooteplein 26, 6500 HB Nijmegen (P.O. Box 9101), The Netherlands

19 E-mail: [johannes.textor@radboudumc.nl](mailto:johannes.textor@radboudumc.nl)

20

## 21 **ABSTRACT**

### 22 **Background**

23 Predicting treatment response or survival of cancer patients remains challenging in immuno-oncology.  
24 Efforts to overcome these challenges focus, among others, on the discovery of new biomarkers.  
25 Despite advances in cellular and molecular approaches, only a limited number of candidate biomarkers  
26 eventually enter clinical practice.

### 27 **Methods**

28 A computational modeling approach based on ordinary differential equations was used to simulate  
29 the fundamental mechanisms that dictate tumor-immune dynamics and to investigate its implications  
30 on responses to immune checkpoint inhibition (ICI) and patient survival. Using *in silico* biomarker  
31 discovery trials, we revealed fundamental principles that explain the diverging success rates of  
32 biomarker discovery programs.

### 33 **Results**

34 Our model shows that a tipping point – a sharp state transition between immune control and immune  
35 evasion – induces a strongly non-linear relationship between patient survival and both immunological  
36 and tumor-related parameters. In patients close to the tipping point, ICI therapy may lead to long-  
37 lasting survival benefits, whereas patients far from the tipping point may fail to benefit from these  
38 potent treatments.

### 39 **Conclusion**

40 These findings have two important implications for clinical oncology. First, the apparent conundrum  
41 that ICI induces substantial benefits in some patients yet completely fails in others could be, to a large  
42 extent, explained by the presence of a tipping point. Second, predictive biomarkers for  
43 immunotherapy should ideally combine both immunological and tumor-related markers, as a patient's  
44 distance from the tipping point can typically not be reliably determined from solely one of these. The  
45 notion of a tipping point in cancer-immune dynamics helps to devise more accurate strategies to select  
46 appropriate treatments for cancer patients.

## 47 INTRODUCTION

48 Immunotherapies are revolutionizing clinical care for cancer patients. The most widely used approach,  
49 immune checkpoint inhibition (ICI), can lead to long-term survival benefits in patients with advanced  
50 melanoma (1), lung cancer (2), and renal cell carcinoma (3). However, not all patients benefit from ICI  
51 therapy, and adequate predictions of treatment response have proven elusive so far (4, 5). Efforts to  
52 improve these predictions focus mainly on discovering biomarkers in aberrant molecular pathways  
53 within the tumor microenvironment that drive immunosuppression and therapeutic resistance (6, 7).  
54 These include genomic alterations in oncogenic drivers, the absence of tumor-specific antigens, and  
55 the presence of immunosuppressive molecules or cells (8, 9). Despite substantial efforts, only a limited  
56 fraction (according to one estimate, <1% (10)) of proposed cancer biomarkers find their way into the  
57 clinical practice. These apparent challenges in identifying biomarkers for immunotherapy and  
58 translating them into clinical practice could be a consequence of the inherent complexity of cancers  
59 and their interaction with the immune system.

60 To unravel the complexities of cancers and their treatments, researchers have adopted mathematical  
61 and computational approaches to complement laboratory research. A plethora of modeling  
62 approaches are available, ranging from simple one-variable equations to complex spatial agent-based  
63 simulation models. *In silico* modeling has contributed to fundamental insights into tumor growth and  
64 cancer progression (11-13), tumor-immune control (e.g., neoantigen prediction as targets for  
65 immunotherapy) (14), identification of tumor-associated genes (15), verification of treatment-related  
66 safety concerns such as hematological toxicity (16), prediction of treatment responses to chemo- and  
67 immunotherapy (17-19), investigation of drug-induced resistance (20), and timing of anti-cancer  
68 treatments (21-23). In the context of disease course dynamics, ordinary differential equation (ODE)  
69 models have proven useful over the years. ODE models follow the principle that a model should be “as  
70 simple as possible but not simpler”. Based on plausible biological assumptions, they aim to reduce the  
71 complex reality of the modeled system to its bare essentials to enable the investigation of critical  
72 underlying dynamics. The field of quantitative systems pharmacology is built upon this premise.  
73 Classically, experimentally-derived pharmacokinetic and pharmacodynamic parameters serve as input  
74 for ODE models to investigate the emergent properties of biological systems and to study its  
75 consequences in terms of clinical outcomes (24). As an illustrative example, Fassoni *et al.* used ODE  
76 models to predict that dose de-escalation of tyrosine kinase inhibitors targeting the oncogenic protein  
77 BCR-ABL1 in patients with chronic myeloid leukemia (chronic phase) does not lead to worse long-term  
78 outcomes (25). The recent results of the DESTINY trial support this prediction (26).

79 In this study, we investigate the consequences of tumor-immune dynamics on patients’ responses to  
80 ICI and survival in an ODE model. Our model reveals a tipping point within tumor-immune dynamics –  
81 a critical threshold for survival culminating in an all-or-nothing principle – that has profound

82 implications for a patient's disease course and outcome. We show how the presence of a tipping point  
83 alone robustly induces heterogeneous immunotherapy treatment outcomes, and how this complicates  
84 the search for both prognostic and predictive biomarkers.

85

## 86 **METHODS**

### 87 **Capturing core mechanisms of tumor development in a mathematical model**

88 We constructed a mathematical model consisting of a system of ordinary differential equations (ODE)  
89 to capture essential interactions between cancer cells and lymphocytes during tumor formation. Our  
90 model represents tumorigenesis in patients, starting with the malignant transformation of a single cell.  
91 The model consists of five equations that describe essential processes in the tumor microenvironment  
92 and the lymphatic organs (Figure 1A). In the tumor microenvironment, tumor growth (Equation 1<sup>a</sup>) and  
93 T cell-mediated killing of tumor cells (Equation 1<sup>b</sup>) determine the evolution of the tumor burden (the  
94 numbers of the equations correspond to those used in Figure 1A). Tumor-infiltrating lymphocytes  
95 migrate from the lymph nodes to the microenvironment (Equation 2). Before migration, T cells expand  
96 clonally in the lymph nodes' T cell zones (Equation 3) after conversion of naive T cells into antigen-  
97 specific effector T cells (Equation 4). Below, we provide in-depth descriptions of each model equation.  
98 We modeled tumor growth – i.e., the formation of tumor cells during carcinogenesis – with the  
99 generalized exponential model proposed by Mendelsohn, in which  $\rho$  represents a tumor growth rate  
100 constant (27). Essentially, this means that at each time interval, a fraction of tumor cells divide. The  
101 dividing fraction decreases as the tumor burden increases since substantial parts of a larger tumor  
102 mass, such as the necrotic core, are no longer able to proliferate. Since the tumor burden ( $T$ ) is  
103 determined by the combination of tumor growth and tumor cell killing, the first part of Equation 1 –  
104 describing the tumor burden over time – will be:

$$105 \quad \text{(Eq. 1<sup>a</sup>)} \quad \frac{dT}{dt} = \rho T^{\frac{4}{5}},$$

106 where  $\frac{dT}{dt} = \rho T^{\frac{4}{5}} = \frac{\rho}{T^{1/5}} T = f(T) T$ , resulting in  $f(T) = \frac{\rho}{T^{1/5}}$  as the fraction of dividing cells per time  
107 interval, which scales inversely with the tumor burden  $T$ .

108 The killing rate expression is derived from the conventional Michaelis-Menten kinetics for enzyme-  
109 substrate interaction (28, 29):



111 in which  $E$ ,  $S$ , and  $P$  are the enzyme, substrate, and product, respectively.  $k_1$ ,  $k_2$ , and  $\xi$  represent the  
112 enzyme-substrate complex formation rate, the complex dissociation rate, and the catalytic rate. Given  
113 that complex formation and dissociation occur at a rate that is at least an order of magnitude faster

114 than tumor growth, Borghans *et al.* argued that the Michaelis-Menten kinetics could be simplified  
115 using a quasi-steady-state assumption (28). Simplification using a Padé approximation and subsequent  
116 rearrangement leads to a conventional Double Saturation (DS) model that describes effector T cell-  
117 mediated killing (28, 29):

$$118 \quad (\text{Eq. 1}^b) \quad \frac{dT}{dt} = -\frac{\xi I T}{1 + \frac{I}{h_I} + \frac{T}{h_T}}$$

119 in which  $I$  is the number of immune cells in the tumor microenvironment,  $\xi$  is the T cell killing rate,  $h_I$   
120 is the saturation constant of the effector T cells, and  $h_T$  is the tumor cells' saturation constant. Here  
121 we consider T cells to follow a 'monogamous killing' strategy, meaning that one T cell interacts with  
122 one tumor cell at a time (28, 29).

123 Combining T cell-mediated tumor cell killing (Equation 1<sup>b</sup>) and tumor growth (Equation 1<sup>a</sup>), we obtain  
124 the complete differential equation that describes the tumor burden over time:

$$125 \quad (\text{Eq. 1}) \quad \frac{dT}{dt} = \rho T^{\frac{4}{5}} - \frac{\xi I T}{1 + \frac{I}{h_I} + \frac{T}{h_T}}$$

126 Subsequently, the immunogenicity of the tumor triggers an anti-tumor immune response. Lymph  
127 node-resident T cells ( $S$ ) migrate at rate  $m_s$  from the lymph nodes to the tumor microenvironment. The  
128 number of intratumoral T cells over time is determined by migration and death. Therefore, by  
129 combining a migration term with a death term at rate  $\delta$ , we obtain the following equation for the  
130 evolution of intratumoral T cells over time:

$$131 \quad (\text{Eq. 2}) \quad \frac{dI}{dt} = m_s S - \delta I$$

132 Intratumoral T cells migrate from the lymph nodes where they are produced. This process starts with  
133 converting lymph node-resident naive T cells (i.e., not activated antigen-specific;  $N$ ) into antigen-  
134 specific effector T cells ( $S$ ) at priming rate  $\alpha$ . The priming rate  $\alpha$  is scaled by the tumor size (i.e., a  
135 smaller tumor will cause less T cell priming than a larger tumor) with a scaling term  $\left(\frac{T}{10^7 + T}\right)$ , meaning  
136 that the priming rate is at half of its maximum rate and starts to saturate in tumors larger than  $10^7$   
137 cells (i.e., a sphere with a radius of 0.29 cm). Effector T cells expand clonally at proliferation rate  $p_s$  and  
138 migrate into the tumor microenvironment. Combining these processes, we arrive at the final two  
139 differential equations that describe the evolution of naïve and primed T cells in the lymph nodes:

$$140 \quad (\text{Eq. 3}) \quad \frac{dS}{dt} = \alpha \left(\frac{T}{10^7 + T}\right) N + p_s S - m_s S$$

$$141 \quad (\text{Eq. 4}) \quad \frac{dN}{dt} = -\alpha \left(\frac{T}{10^7 + T}\right) N$$

142 The simulations used the following initial conditions:  $T(0) = 1$ ,  $I(0) = 0$ ,  $S(0) = 0$ , and  $N(0) = 10^6$ .

143

## 144 Simulation parameters

145 The simulation parameters are listed in Table 1.

146 Table 1: Simulation parameters in the ODE model

Symbol	Parameter (dimension)	Default value (range <sup>a</sup> )
$\rho$	Tumor growth rate (cells day <sup>-1</sup> )	1 (0-7)
$\xi$	Relative killing rate (cells day <sup>-1</sup> )	0.001 (0-0.05)
$h$	Michaelis constant (cells)	571
$\delta$	Death rate of immune cells (cells day <sup>-1</sup> )	0.019 (30)
$\alpha$	Conversion rate of naive T cells into specific T cells (cells day <sup>-1</sup> )	0.0025
$p_s$	Total production rate of effector T cells from lymph nodes (cells day <sup>-1</sup> )	1
$m_s$	Migration rate from lymph node to tumor microenvironment (cells day <sup>-1</sup> )	1

147 <sup>a</sup>: if not fixed

148

149 The parameters were chosen to mimic realistic *in vivo* intercellular behavior. The rationale for the  
150 choice of each parameter is explained below.

151 In a human adult, an estimated repertoire of approximately  $10^{10}$  -  $10^{11}$  naive CD8<sup>+</sup> T cells is present (31,  
152 32). Naive CD8<sup>+</sup> T cells need to be primed to become activated effector T cells. The CD8<sup>+</sup> T cell precursor  
153 frequency – the frequency at which any given peptide-MHC complex is recognized by naive antigen-  
154 specific CD8<sup>+</sup> T cells – is on the order of 1 : 100.000 (31). Priming should be limited primarily to naive  
155 CD8<sup>+</sup> T cells in one of the tumor areas draining lymph nodes. A human body contains  $\pm 600$  lymph  
156 nodes. At a steady state, roughly 40% of all lymphocytes reside in lymph nodes, meaning that 40.000  
157 naive T cells ( $\approx 70$  naive CD8<sup>+</sup> T cells per lymph node) can be primed (33, 34). We assume that priming  
158 occurs primarily in the tumor-draining lymph node station (per station harboring around 20 lymph  
159 nodes (35)). Then, 1400 T cells would be available for priming at any given time, and this pool would  
160 be refreshed approximately once per day by T cell recirculation. Considering that dendritic cells might  
161 present multiple epitopes and antigens, and that T cell priming *in vivo* might occur suboptimally, we  
162 set a priming rate of at most 2500 cells per day. The order of magnitude of these priming rates  
163 corresponds to priming rates found in chronic infectious diseases (36). Due to evasive mechanisms,  
164 anti-tumor immunity is a more dormant process than an immune response to infections (37).  
165 Therefore, we scaled the priming rate with tumor size, which translates into a maximum production  
166 of  $10^6$  antigen-specific CD8<sup>+</sup> T cells per day via clonal expansion. Next, we assume that all antigen-  
167 specific effector T cells migrate into the tumor microenvironment to interact with tumor cells (i.e.,  
168 complex formation).

169 Complex formation and dissociation rates are described by the ‘Michaelis constant’, which we derived  
170 from the literature (29). The Michaelis constant describes the ratio between complex formation and  
171 dissociation.

172 The killing rate of effector T cells has been investigated mainly in the context of infectious disease. In  
173 their review (38), Halle *et al.* discuss discrepancies between *in vitro* and *in vivo* killing rates of effector  
174 T cells. Depending on the context, killing rates of effector T cells vary from 1 target per 5 minutes to 0-  
175 10 targets per day (38), but tumor cells are considered difficult to kill. Extensive variation in  
176 experimental *in vivo per capita* killing rates (i.e., the number of cells killed by an effector T cell per unit  
177 of time) complicates the selection of a default fixed killing parameter. Therefore, we investigated T cell  
178 dynamics over a wide range of killing rates as described using the monogamous killing regime in a  
179 double saturation model by Gadhamsetty *et al.* (29). The double saturation model ensures that the  
180 killing rate saturates with respect to the tumor cell and the effector cell densities. Consequently, our  
181 model’s maximum per capita killing rate is 2.5: one T cell can kill at most 2.5 tumor cells per day,  
182 provided there are abundant target cells available, and there is no competition with other T cells. The  
183 default tumor growth rate is one cell day<sup>-1</sup>, but we varied this parameter extensively in our simulations.  
184 Taken together, our default parameter values led to simulations of disease courses with realistic  
185 survival times in patients with malignancies and matched the order of magnitude of tumor growth  
186 rates as reported by others (39).

187

### 188 **Time-varying parameters**

189 For the simulations shown in Figures 4 and 5, we varied the tumor growth rate  $\rho$  and the T cell killing  
190 rate  $\xi$  in a stochastic manner over time. Briefly, we set one value per month of simulated time by  
191 multiplying the baseline parameter value with a random number drawn from a normal distribution  
192 with a fixed standard deviation. The values used for the standard deviations are given in  
193 Supplementary Tables 4 and 5 (“stochasticity”). From these monthly reference values, we generated  
194 time-dependent functions using cubic B-spline interpolation. For details, see our simulation code (link  
195 given below).

196

### 197 **Patient simulations**

198 We simulated tumor development in patients up to a maximum of 5 years. Note that depending on  
199 emergent tumor-immune dynamics, simulated patients may not reach the overall survival endpoint  
200 during this interval. Each time step in the simulation corresponded to one day. At baseline, one tumor  
201 cell and a pool of  $10^6$  naïve tumor-specific T cells are present in a patient. Activated effector T cells are  
202 absent. We defined the time of diagnosis as the time at which the tumor exceeded  $65 * 10^8$  cells and

203 became clinically apparent. This cut-off corresponds to the assumption that a tumor with a volume of  
204  $1 \text{ cm}^3$  contains  $10^8$  tumor cells (40) and that several primary tumors (e.g., lung cancer, colon carcinoma,  
205 and renal cell carcinoma) are diagnosed as spherical structures with a median diameter of  
206 approximately 5 cm (41-43). The 'lethal' tumor burden of patients in these simulations is estimated at  
207  $10^{12}$  cells, corresponding to a total tumor mass of approximately  $22 * 22 * 22 \text{ cm}$ .

208

### 209 **Validation cohort**

210 Model findings related to biomarker discovery programs were validated in a cohort of 58 patients with  
211 metastatic cutaneous melanoma that were treated with dendritic cell vaccination. Full details of this  
212 cohort, including baseline characteristics, were published previously (44). None of the patients  
213 received prior or subsequent immunotherapy. The serum lactate dehydrogenase levels at baseline  
214 (i.e., before therapy) were analyzed as a surrogate marker for tumor growth. The ratio of intratumoral  
215 versus peritumoral T cell densities (I/P ratio), obtained by immunohistochemical staining of the  
216 primary tumor, was selected as a surrogate marker for the T cell killing rate. Overall survival data were  
217 available for all patients.

218

### 219 **Model implementation**

220 We implemented our ODE model in C++. The Boost library 'odeint' was used to solve the system of  
221 ordinary differential equations (45). The code is available at GitHub:  
222 <https://github.com/jeroencreemers/tipping-point-cancer-immune-dynamics>. Analyses and  
223 visualizations were performed in R.


224

## 225 **RESULTS**

### 226 **Modeling tumor-immune dynamics yields realistic disease trajectories**

227 To investigate the consequences of tumor-immune dynamics on the survival kinetics of patients, we  
228 used a computational modeling approach. We aimed to capture the interplay between tumor- and  
229 immune cells in the tumor microenvironment and simulate tumor growth in patients (see Methods).  
230 Our ODE model captured essential processes in anti-tumor immunity: priming of naive antigen-specific  
231  $\text{CD8}^+$  T cells, clonal expansion of effector T cells in lymph nodes, tumor growth leading to effector T  
232 cell attraction into the tumor microenvironment, and formation of tumor-immune cell complexes to  
233 enable tumor cell killing (Fig. 1A).





234

235 **Figure 1: An in silico model of the tumor microenvironment generates realistic and modifiable disease courses of cancer**  
 236 **patients.**

237 **(A)** The ODE model describes fundamental processes in the tumor microenvironment. Parameters:  $\alpha$  = naive T cell priming  
 238 rate,  $\delta$  = effector T cell death rate,  $\xi$  = effector T cell killing rate,  $\rho$  = tumor growth rate,  $p_s$  = effector T cell proliferation rate,  
 239 and  $m_s$  = effector T cell migration rate. **(B)** An effective anti-tumor immune response can eradicate tumor cells before the  
 240 clinical manifestation of a tumor. **(C)** After an initial state in which the tumor outpaces the immune system, the immune system  
 241 can suppress tumor growth and controls it in a subclinical state. **(D)** The natural course of disease for a clinically apparent  
 242 tumor. An initial malignant transformation is followed by tumor growth until clinical diagnosis. Despite the activation of  
 243 adaptive immunity, the tumor prevails. A stage of progressive disease follows, ultimately culminating in cancer-related death.  
 244 The horizontal grey lines indicate (from bottom to top): the tumor burden at diagnosis and the tumor burden at death,  
 245 respectively. Simulation parameters are added in Supplementary Table 1.

246 We simulated tumor development from malignant transformation of a single cell, via clinical detection  
 247 of a tumor, to advanced disease and possibly death. Depending on the tumor growth and the cytotoxic  
 248 capacity of effector T cells, the ‘time to clinical manifestation’ and overall survival varied. Despite this  
 249 variation, our simulations consistently showed three possible outcomes: 1) effector T cells inhibited  
 250 tumor cell outgrowth and eradicated the tumor before clinical manifestation (Figure 1B); 2) effector T  
 251 cells were initially unable to inhibit tumor cell outgrowth but caught up and suppressed tumor growth  
 252 to a balanced subclinical state (Figure 1C); or 3) exponential tumor growth outpaced the immune  
 253 system’s control and gave rise to a clinically detectable tumor (Figure 1D). These three scenarios only  
 254 led to two clinically different outcomes in patients: either a tumor became clinically evident, or the  
 255 immune system could suppress or eradicate a tumor at an early stage (i.e., before the tumor could



256 reach a clinically detectable size). A balanced equilibrium state, in which the immune system keeps a  
257 clinically evident tumor under persistent control, does not exist in this deterministic version of our  
258 model.

259

### 260 **Patient survival depends on a tipping point in tumor-immune dynamics**

261 To better characterize these dichotomous survival kinetics, we examined how tumor-immune  
262 dynamics influenced patient survival by varying the tumor growth rate and the T cell killing rate over  
263 a broad range of possible values.

264 First, we focused solely on the tumor-component by varying the tumor growth rate. An increase in  
265 tumor growth did not gradually shorten overall survival in patients (Figure 2A). On the contrary, a  
266 critical threshold was present. Once the threshold was exceeded, the kinetics ‘flipped’ from a state of  
267 immune control (Figure 2A, inset 1) to a state in which the tumor could evade immune control (Figure  
268 2A, inset 2).


269 Second, we investigated the influence of the T cell killing rate on overall survival. As for the death rate,  
270 a gradual increase in the cytotoxic capacity of effector T cells did not induce a gradual change in survival  
271 times. Instead, a sharp state transition that differentiated short from long survival was observed again  
272 (Figure 2B). This coincided with the phenotypes ‘immune evasion’ (Figure 2B, inset 1) and ‘immune  
273 control’ (Figure 2B, inset 2).

274 To visualize this sudden state transition or ‘tipping point’ in tumor-immune dynamics as a function of  
275 both tumor proliferation and cytotoxic killing at the same time, we visualized the joint influence of the  
276 tumor growth rate and T cell killing rate on survival in a heatmap (Figure 2C). This ‘phase diagram’  
277 shows that the tipping point is not only present for specific parameter values but is a fundamental  
278 property in our model. By contrast, the state of subclinical tumor control was not universally present  
279 around the tipping point (Figure 2C, inset) but manifested itself only in a narrow range of parameters.  
280 Within both the ‘Cure’ and ‘Control’ domain (Figure 2, inset), the immune system prevented tumors  
281 from reaching a detectable size, precluding the clinical classification as ‘patient’. The difference  
282 between individuals in the ‘Cure’ and ‘Control’ domains was that all tumor cells were eradicated in the  
283 former, while in the latter, the immune system kept the tumor in an undetectable subclinical state  
284 (i.e., a tumor size of around  $10^3$  tumor cells; Figure 1B/C).

285 Next, we expanded these analyses to characterize the tipping point in different tumor types. A  
286 fundamental distinction between tumors is the rate at which they induce T cell priming, for instance,  
287 through tumor-specific immunogenicity or by specific characteristics of the immunosuppressive  
288 microenvironment. To this end, we simulated four tumor types: a tumor without T cell priming and  
289 three tumors in which T cell priming was varied from low to high. Without T cell priming, survival was  
290 only determined by the tumor growth rate – logically, no tipping point exists in the absence of T cells

291 (Supplementary Figure 1A). With T cell priming, tipping points became apparent. The location of the  
 292 tipping point was affected by the priming rate. A higher priming rate facilitated improved tumor  
 293 eradication through an increased influx of cytotoxic T cells into the tumor microenvironment  
 294 (Supplementary Figure 1B-D).

295 In general, the presence of a tipping point indicates that small perturbations in either tumor growth  
 296 rate or T cell killing rate in the vicinity of a tipping point may result in substantial overall survival  
 297 differences in patients. In contrast, much larger perturbations far away from the tipping point would  
 298 have far less effect.




299  
 300 **Figure 2: A tipping point in the tumor-immune interaction determines a patient's outcome.**  
 301 (A) A gradual increase in tumor growth reveals a tipping point, where long-term survival (immune control; inset 1) abruptly  
 302 changes to short-term survival (immune evasion; inset 2). (B) A similar analysis reveals a tipping point along the immune axis,  
 303 again differentiating short-term survival (immune evasion; inset 1) from long-term control (immune control; inset 2). (C) The  
 304 tipping point is present across the entire range of parameters examined. Cure and progressive disease are the dominant states,  
 305 whereas subclinical tumor control only occurs within a limited parameter range (inset). Simulation parameters are shown in  
 306 Supplementary Table 2.

307  
 308 **Immune checkpoint inhibitors induce a survival benefit by shifting patients over a tipping**  
 309 **point**

310 So far, we have described tumor-immune interactions during the natural course of malignant disease.  
 311 In a clinical setting, however, therapeutic interventions are available to steer disease courses.

312 Dependent on the treatment of choice, a specific effect is exerted on the tumor microenvironment.  
 313 Treatment effects vary from constraining the proliferative capacity of tumor cells (e.g., chemotherapy  
 314 or targeted therapy) to increasing the T cell pool (e.g., CAR T cells) or expanding the proliferative  
 315 capacity of T cells (e.g., cancer vaccines; Figure 3A). Given the unparalleled responses of advanced  
 316 malignancies to immunotherapy, we focused on the consequences of a tipping point for responses to  
 317 immune checkpoint inhibitors (ICI), but these findings could be extended to other therapies as well. In  
 318 this study, we limited the treatment effect of ICI to their primary mode of action: the augmentation of  
 319 the T cell killing rate (Figure 3A).



320

321 **Figure 3: Tipping points induce dichotomous clinical outcomes in heterogeneous patient populations.**

322 (A) Treatments target processes or cell populations in the tumor microenvironment. (B-C) Two criteria need to be met to  
 323 induce long-term survival: (B) ICI need to augment T cell killing sufficiently, and (C) the treatment effect needs to be retained  
 324 for a prolonged time. An inadequate treatment effect or limited treatment duration led at maximum to a temporary survival  
 325 benefit. (D-E) In patient populations with variation in only (D) the tumor (i.e., growth rate), or (E) the immune system (i.e., T  
 326 cell killing rate), the distance to a tipping point determines the clinical benefit. Without treatment, survival was limited (grey

327 bars). In contrast, ICI induced long-term survival solely in patients close to a tipping point (green bars). See also Supplementary  
328 Table 3.


329  
330 In the presence of a tipping point, ICI could induce a long-term survival benefit under two conditions:  
331 1) the effect of treatment needs to be potent enough to shift a patient over a tipping point (Figure 3B),  
332 and 2) the treatment effect needs to be sustained long enough for a patient to benefit from the  
333 treatment (Figure 3C). The treatment effect was defined as the multiplication factor of the T cell killing  
334 rate. When both criteria were satisfied, ICI were able to induce a long-term survival benefit. However,  
335 if the treatment effect (anti-PD1 effect < 12.6) or duration (less than  $\pm 5$  months) proved inadequate,  
336 any survival benefit was only temporary, and inevitable tumor progression would ultimately limit  
337 overall survival (Figure 3B/C; insets). These survival kinetics depend not solely on therapeutic features  
338 of ICI but rather on the interplay between patient and ICI characteristics. To illustrate this, we  
339 simulated twenty patients with identical immune systems (i.e., identical T cell killing rates). In the  
340 absence of ICI therapy, variation in the tumor growth rate – that is, variation in the distance to a tipping  
341 point – led to a limited variation in survival (Figure 3D; grey bars). When these same patients were  
342 treated with ICI, a survival benefit is induced in all patients. However, the extent of this benefit differs  
343 and depends on the distance to a tipping point. Following clinical observations, long-term survival is  
344 only induced in the subset of patients close to a tipping point (Figure 3D; green bars). Similar findings  
345 were obtained in a population of patients with identical tumors but different immune systems.  
346 Without treatment, hardly any survival variation is present (Figure 3E; grey bars). Again, treatment  
347 with ICI induced dichotomous clinical outcomes: a small survival benefit in most patients, with long-  
348 term survival in a subset (Figure 3E; green bars). Hence, the mere presence of a tipping point yields  
349 heterogeneity in treatment outcomes.

350

### 351 **Tipping points determine patient outcomes in dynamic patient trajectories**

352 Thus far, our simulations considered tipping points generated in patients with fixed characteristics.  
353 However, disease courses in patients are certainly not fixed and are, to a certain extent, subject to  
354 (possibly random) variation. We hypothesized that interpatient variability in clinical outcomes could  
355 be partially attributable to this dynamic behavior of cancers and the interaction with the immune  
356 system. Such variation might reflect biological processes (e.g., accumulating mutations, the expression  
357 of checkpoint molecules, and the availability of nutrients) that alter anti-tumor immunity and promote  
358 or hamper tumor development. We reasoned that the subsequent dynamics could drive patients  
359 towards and ultimately over a tipping point – or move patients away from it, which would limit the  
360 survival benefit of these treatments. To verify this hypothesis, we simulated the effect of dynamically  
361 evolving tumors (Figure 4A) or immune systems (Figure 4B) in identical patients compared to a static  
362 reference patient. Specifically, we varied the tumor growth rate and the T cell killing rate randomly

363 over time (parameter values are included in Supplementary Table 4). Upon reaching a diagnosable  
 364 tumor volume, all patients in these examples were treated with ICI. As expected, stochastic dynamics  
 365 prompted survival differences and induced a survival benefit in a subset of patients. In a  
 366 heterogeneous patient population, this led to an interesting finding: the initial distance to a tipping  
 367 point, along with the dynamics itself, determined the clinical outcome of patients treated with ICI  
 368 (Figure 4C, Supplementary Figure 2). At population level, this led to a distinction between three subsets  
 369 of patients: (1) patients far away from a tipping point with an unmodifiable bad prognosis (non-  
 370 responders), (2) patients close to a tipping point with a favorable prognosis (responders), and, most  
 371 importantly, (3) patients in between these groups (potential responders). In the last subset, tumor  
 372 dynamics ultimately determined the treatment response, and thereby the clinical outcome (Figure 4C;  
 373 grey box). A clinically important ramification of dynamic trajectories is that even if the subset to which  
 374 a patient belongs is known at baseline, dynamics could alter the distance to a tipping point and,  
 375 thereby, the prognosis of a patient. Therefore, it might be impossible to predict the prognosis solely  
 376 based on characteristics measured upon diagnosis. Dynamic trajectories can significantly diversify  
 377 patient outcomes, meaning that continuous variation in the tumor growth rate (Figure 4D) or T cell  
 378 killing rate (Figure 4E) leads to an entire spectrum of patient outcomes.




379

380 **Figure 4: Survival outcomes are strongly affected by evolving patient dynamics.**

381 (A-B) Examples of dynamic disease courses in patients with identical tumors and immune systems at baseline, respectively.  
 382 (A) Evolving tumors (i.e., random variation in tumor growth rate over time) and (B) continuous variation in the potency of the  
 383 immune system (i.e., killing rate) lead to divergent survival outcomes. The grey dotted lines indicate the baseline values for  
 384 the growth rate and killing rate, respectively. (C) Dynamic trajectories in a heterogeneous patient population can move  
 385 patients towards or away from a tipping point. The grey box indicates patients in which dynamic trajectories strongly alter  
 386 survival outcomes. See also Supplementary Figure 2. In dynamic trajectories, (D) baseline tumor growth and (E) baseline T cell  
 387 killing rates cannot accurately predict overall survival. Note: all patients in these examples are treated with ICI. The red and  
 388 black dotted lines indicate the 25% and 75% quantiles, respectively. See also Supplementary Table 4.

### 389 Implications of tipping points for biomarker discovery studies

390 Biomarker discovery studies aim to improve the prediction of patient survival upon treatment. We  
 391 observed that tipping points are crucial in shaping survival kinetics. Therefore, accurate survival  
 392 predictions would require the consideration of tipping points. Ideally, a prognostic biomarker (or  
 393 biomarker panel) would consistently distinguish long-term survivors from their counterparts. Since the  
 394 non-linear survival dynamics following a tipping point weaken the correlation between a single  
 395 biomarker and survival, the question is: how can we screen for biomarkers in a more efficient manner  
 396 that takes this tipping point into account?



397

#### 398 **Figure 5: Non-linear tumor-immune dynamics complicate biomarker discovery.**

399 **(A)** An *in silico* biomarker discovery study in a 'fixed' patient cohort: while a single biomarker – either a tumor or an immune  
 400 marker – can predict survival to some extent (the first and second columns), information from both markers in a biomarker  
 401 panel enhances the predictive capacity greatly (third column). **(B)** Dynamic disease trajectories challenge survival prediction  
 402 with 'baseline' biomarkers. In dynamic disease courses, the predictive value of single 'baseline' biomarkers is limited (the first  
 403 and second columns; compare to Figure 5A). A biomarker panel improves survival predictions in this cohort (the third column)  
 404 but is still defied by evolving dynamics. See also Supplementary Table 5.

405




406 At first, we approached this question with an *in silico* biomarker discovery study. We measured the  
407 value of two potential biomarkers at baseline in simulated patients (n=100) that were subsequently  
408 treated with ICI (cohort characteristics are specified in Supplementary Table 5). We simplified the  
409 cohort by fixing the tumor and immune characteristics of these patients over time and assumed to  
410 have access to an entirely accurate biomarker (i.e., no measurement error; Figure 5A). Within this  
411 cohort, we predicted the prognosis of patients based on either the tumor or immune marker (the first  
412 and second columns of Figure 5A, respectively). As is common in practice (though from a statistical  
413 point of view far from ideal), we dichotomized the biomarker using its median as a cut-off. Although  
414 survival differentiation based on these biomarkers alone was partially possible, it remained far from  
415 optimal. However, when we constructed a biomarker panel including both biomarkers, it highly  
416 accurately discriminated short-term from long-term survivors (third column of Figure 5A). Note that  
417 despite variability in time from diagnosis, the initial plateau in the survival curves was caused by the  
418 fact that all tumors were diagnosed with identical sizes and immediately treated.

419 In clinical practice, the assumption of a ‘fixed’ patient trajectory does not hold. Therefore, we  
420 simulated this cohort again with dynamic trajectories. Due to the dynamics, a subgroup of patients did  
421 not develop clinical tumors and was excluded from the analysis. The prediction of a patient’s prognosis  
422 with a single biomarker, either from the tumor or the immune system, in a dynamic cohort became  
423 increasingly challenging (the first and second columns of Figure 5B). The combination of both markers  
424 in a biomarker panel increased the predictive capacity slightly, enabling the prediction of prognosis to  
425 some extent. However, in line with the notion of personalized medicine, the accurate and  
426 individualized prediction of prognosis based on baseline characteristics was not feasible in a significant  
427 subgroup of patients due to dynamic tumor-immune interactions (third column of Figure 5B).

428 These *in silico* experiments suggest that biomarker discovery efforts benefit from considering tumor  
429 and immune markers in concert rather than alone. To test this hypothesis, we retrospectively analyzed  
430 clinical data derived from previous trials in patients with metastatic melanoma (n = 58; see baseline  
431 characteristics in Supplementary Table 6) (44). We assessed whether a combination of two biomarkers  
432 would provide more information on a patient’s survival than either marker alone. Baseline lactate  
433 dehydrogenase (LDH) was selected as a surrogate marker for tumor growth, and the ratio between  
434 immunohistochemically-determined intratumoral vs. peritumoral immune cells (I/P ratio) on the  
435 primary tumor was selected as an immune marker. We then used two different methods to measure  
436 the amount of information these markers provide on patient survival. First, we applied linear  
437 discriminant analysis to determine marker cut-off values that distinguish “short survivors” (<9 months)  
438 from “long survivors” (>9 months, corresponding to the median survival in the cohort). A cut-off based  
439 on the tumor marker LDH alone correctly classifies 71% of patients (Figure 6A), which increased to 78%  
440 when using the I/P ratio as an immune marker instead. A combination of both markers achieves 86%



441 accuracy, with the discrimination line following a roughly diagonal slope akin to the tipping point in  
 442 our “in silico” cohort (Figure 2).



443  
 444 **Figure 6: A composite biomarker consisting of a tumor and an immune component outperforms single markers in a**  
 445 **retrospective analysis of metastatic melanoma patients.**  
 446 (A) A linear classifier based on LDH level at baseline, a surrogate marker for tumor growth, classified 71% of all patients  
 447 correctly as short survivors (<9 months) or long survivors (>9 months). With an accuracy of 78%, the I/P ratio – an immune  
 448 marker – performs better in this cohort. A linear combination of both markers leads to an even better classification (86%  
 449 accuracy) than either one alone. (B) A Cox proportional hazard model based on both markers fits the data better than models  
 450 based on either marker as measured by the Bayesian Information Criterion (BIC) (the lower, the better, and differences above  
 451 10 are considered strongly favoring one model over another).

452  
 453 Second, we compared Cox proportional hazard models based on LDH alone and I/P ratio alone to a  
 454 model including both markers. Both LDH (likelihood ratio test:  $p=4 \times 10^{-7}$ ) and I/P ratio ( $p=3.6 \times 10^{-7}$ )  
 455 explained survival better than chance on their own, but a bivariable model ( $p=9.3 \times 10^{-10}$ ;  
 456 Supplementary Table 7) provided the best fit to the data as measured by a Bayesian Information  
 457 Criterion (BIC), which was lower by 11.6 compared to the LDH-only model and by 20.7 compared to  
 458 the I/P ratio-only model. The Kaplan-Meier plots shown in Figure 6B illustrate the performance of each  
 459 model by comparing the patients with the highest 50% estimated relative hazard to the lowest 50%.  
 460 These results support our *in silico*-generated hypothesis that a combination of tumor and immune  
 461 markers form a better basis for patient stratification than either marker on its own.  
 462 Two important findings are derived from these observations: First, due to the non-linear tumor-  
 463 immune dynamics with respect to survival, it can be complicated for a single biomarker to predict a  
 464 patients’ prognosis accurately. Since survival kinetics emerge from the interplay between a cancer and

465 the immune system, biomarkers from both systems need to be incorporated simultaneously into a  
466 biomarker panel to improve the predictive value. Second, biomarker measurements at baseline are  
467 merely a situational snapshot of the disease conditions *at a specific point in time*. Depending on the  
468 magnitude of the dynamics, it might become challenging or even impossible to predict the prognosis  
469 of patients from these biomarkers correctly.

470

## 471 **DISCUSSION**

472 This study investigated how tumor-immune dynamics relate to ICI-induced treatment responses and  
473 survival kinetics of patients. We predict that a tipping point is present in the tumor-immune  
474 interaction. This finding implies that underneath the intricate interplay between a developing  
475 malignancy and the immune system, two contrasting disease states determine disease outcome: a  
476 state where the immune system controls tumor outgrowth and a state in which a tumor escapes  
477 immune defense. A stable “steady state” in which tumor growth and the immune response perfectly  
478 balance each other for extended periods seems only plausible in a subclinical setting. We show that  
479 treatment with ICI can induce a survival benefit by shifting a patient over a tipping point, thereby  
480 tipping the balance in tumor-immune dynamics in favor of survival. In line with clinical observations of  
481 interpatient variability in disease courses, we found that dynamics in patient trajectories pose major  
482 challenges for treatment response prediction. Moreover, we showed how the tipping point in dynamic  
483 patient trajectories defies simple strategies for outcome prediction in biomarker discovery studies. In  
484 particular, when facing highly dynamic disease courses, adaptive treatment strategies based on  
485 continuous monitoring might be more promising than simple patient stratification at baseline.

486 Tipping points are well-known in complex systems such as financial markets and ecosystems but are  
487 also present in medicine (46, 47). State transitions might progress gradually or abruptly. If a system  
488 balances around a critical threshold, small perturbations might induce an abrupt transition to a  
489 contrasting state. In oncology, phenomena like partial or complete radiologic responses during  
490 treatment or (hyper)progression after discontinuation of treatment suggest the presence of state  
491 transitions (48, 49). Based on these observations, a tipping point in cancer immunotherapy had been  
492 speculated upon (50). Experimentally, tipping points are most clearly represented by early preclinical  
493 work in the PD-1/PD-L1 axis. Consistent with our findings, dichotomous treatment responses arise in  
494 syngeneic DBA/2 mice inoculated with P815/PD-L1 cells (51). While genetically identical with similar  
495 tumor characteristics, anti-PD-L1 antibodies prolong survival in only a subset of the mice, likely due to  
496 stochastic differences in immune responses and TCR repertoire. Additional *in vivo* data supporting the  
497 theory of tipping points in oncology is derived from studies on dynamic network biomarkers, showing  
498 its relevance during the onset of metastasis in hepatocellular carcinoma (52) and the development of

499 treatment resistance in breast cancer (53). This study provides a potential mechanistic explanation for  
500 this phenomenon in immuno-oncology and shows its implications on the induction of long-term  
501 survival in clinical practice and biomarker discovery. From a biomechanistic perspective, such state  
502 transitions in cancer immunotherapy arise due to fundamental differences in proliferation kinetics  
503 between tumors and the immune system. While tumor cell proliferation is virtually unrestricted,  
504 immune cell proliferation is much more limited and tightly controlled. Our finding that tipping points  
505 affect not only natural disease courses but also treatment responses underlines the importance of  
506 these kinetics.

507 Tipping points within tumor-immune dynamics have important implications for biomarker discovery.  
508 Biomarkers are developed to predict prognosis and steer clinical decision-making. Disease outcomes  
509 in cancer patients are essentially determined by the interplay between two complex systems: the  
510 tumor and the immune system. Our model predicts that factors from both systems should be  
511 considered to improve the predictive power of biomarkers. However, in contrast with this seemingly  
512 straightforward prediction, current research mainly focuses on factors derived from one of the two  
513 complex systems. Expression of programmed death ligand-1 (PD-L1) on tumor tissue illustrates this:  
514 while 45% of patients with PD-L1 positive tumors show objective responses to anti-PD(L)1  
515 immunotherapy, 15% of patients with PD-L1 negative tumors also show objective responses (54).  
516 Other explanations for this difference include heterogeneous intratumoral and inter-metastases  
517 expression patterns, positivity-threshold selection, and differences in immunohistochemical staining  
518 protocols. In that respect, tumor mutational burden (TMB) might prove to be a highly relevant  
519 biomarker. The mutation rate is a tumor-intrinsic factor associated with the phenotypical  
520 aggressiveness of tumors (55). Simultaneously, a high mutational burden might induce a plethora of  
521 neoantigens, linking this tumor-intrinsic factor directly to adaptive immunity. Clinical observations of  
522 a stronger association between TMB and response rates to anti-PDL1 immunotherapy compared to  
523 PD-L1 expression in patients with urothelial carcinoma support this hypothesis (56). Our research thus  
524 reinforces common calls to integrate multiple biomarkers for immunotherapy prediction outcomes  
525 (57, 58); at least, a combination of both immunological and tumor-related parameters should be the  
526 basis of *any* biomarker discovery effort. The strongly non-linear dynamics resulting from the tipping  
527 point mean that a one-dimensional approach will likely be insufficient.

528 Our approach has to be interpreted in light of some limitations. Although the ‘coarse-grained’ nature  
529 of ODE models allows focusing on the major common underlying mechanisms in many cancers, it is  
530 also a potential pitfall. For example, metabolic processes such as hypoxia, immune-suppressive  
531 characteristics of the tumor microenvironment such as the presence of FoxP3<sup>+</sup> regulatory T cells or  
532 expression of transforming growth factor  $\beta$ , the presence of other relevant effector cells such as  
533 natural killer cells, and the availability of nutrients are only implicitly represented by our model in a

534 single killing efficacy parameter. This simplification also holds for treatments. In this study, ICI was  
535 limited to its main mode of action: the augmentation of the T cell killing rate. While the ‘true’  
536 mechanistic effects might be more widespread, sufficient data to correctly parameterize more  
537 complex models remains scarce. Furthermore, it should be emphasized that an ODE model contains  
538 limited spatial information; while we distinguish between lymphatic tissue and the tumor  
539 microenvironment, all cells within the microenvironment are identical, and all processes affect cells in  
540 the same manner. Although we do not expect that explicit incorporation of these processes or  
541 translation of the model into a spatial variant alters our central finding of a tipping point, it could  
542 nevertheless be of interest to verify these hypotheses in future research using more complex, spatial  
543 agent-based models.

544 In conclusion, we used computational modeling to show that the clinical outcome of cancer patients  
545 is determined by tipping points in tumor-immune dynamics. A tipping point influences not only  
546 treatment response but also the prognosis of patients and has major implications for future biomarker  
547 research.

## 548 REFERENCES

- 549 1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and  
550 Ipilimumab in Advanced Melanoma. *N Engl J Med*. 2019;381(16):1535-46.
- 551 2. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-  
552 Small-Cell Lung Cancer. *N Engl J Med*. 2019;381(21):2020-31.
- 553 3. Motzer RJ, Escudier B, McDermott DF, et al. Survival outcomes and independent response  
554 assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell  
555 carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. *J Immunother Cancer*. 2020;8(2).
- 556 4. Aly A, Mullins CD, Hussain A. Understanding heterogeneity of treatment effect in prostate  
557 cancer. *Curr Opin Oncol*. 2015;27(3):209-16.
- 558 5. Kent DM, Alsheikh-Ali A, Hayward RA. Competing risk and heterogeneity of treatment effect  
559 in clinical trials. *Trials*. 2008;9:30.
- 560 6. Bedard PL, Hansen AR, Ratain MJ, et al. Tumour heterogeneity in the clinic. *Nature*.  
561 2013;501(7467):355-64.
- 562 7. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. *Nat Rev*  
563 *Clin Oncol*. 2018;15(2):81-94.
- 564 8. Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, Adaptive, and Acquired Resistance to  
565 Cancer Immunotherapy. *Cell*. 2017;168(4):707-23.
- 566 9. Roskoski R, Jr. A historical overview of protein kinases and their targeted small molecule  
567 inhibitors. *Pharmacol Res*. 2015;100:1-23.
- 568 10. Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable  
569 diversity in biomarker failures. *Cancer Res*. 2012;72(23):6097-101.
- 570 11. Murphy H, Jaafari H, Dobrovolsky HM. Differences in predictions of ODE models of tumor  
571 growth: a cautionary example. *BMC Cancer*. 2016;16:163.
- 572 12. Edelman EJ, Guinney J, Chi JT, et al. Modeling cancer progression via pathway dependencies.  
573 *PLoS Comput Biol*. 2008;4(2):e28.
- 574 13. Baratchart E, Benzekry S, Bikfalvi A, et al. Computational Modelling of Metastasis Development  
575 in Renal Cell Carcinoma. *PLoS Comput Biol*. 2015;11(11):e1004626.
- 576 14. De Mattos-Arruda L, Vazquez M, Finotello F, et al. Neoantigen prediction and computational  
577 perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working  
578 Group. *Ann Oncol*. 2020;31(8):978-90.
- 579 15. Pujana MA, Han JD, Starita LM, et al. Network modeling links breast cancer susceptibility and  
580 centrosome dysfunction. *Nat Genet*. 2007;39(11):1338-49.
- 581 16. Friberg LE, Henningson A, Maas H, et al. Model of chemotherapy-induced myelosuppression  
582 with parameter consistency across drugs. *J Clin Oncol*. 2002;20(24):4713-21.
- 583 17. Lee JJ, Huang J, England CG, et al. Predictive modeling of in vivo response to gemcitabine in  
584 pancreatic cancer. *PLoS Comput Biol*. 2013;9(9):e1003231.
- 585 18. Wang HW, Milberg O, Bartelink IH, et al. In silico simulation of a clinical trial with anti-CTLA-4  
586 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model.  
587 *Roy Soc Open Sci*. 2019;6(5).
- 588 19. Valentinuzzi D, Simoncic U, Ursic K, et al. Predicting tumour response to anti-PD-1  
589 immunotherapy with computational modelling. *Phys Med Biol*. 2019;64(2):025017.
- 590 20. Sun X, Bao J, Shao Y. Mathematical Modeling of Therapy-induced Cancer Drug Resistance:  
591 Connecting Cancer Mechanisms to Population Survival Rates. *Sci Rep*. 2016;6:22498.
- 592 21. Zhang J, Cunningham JJ, Brown JS, et al. Integrating evolutionary dynamics into treatment of  
593 metastatic castrate-resistant prostate cancer. *Nat Commun*. 2017;8(1):1816.
- 594 22. Cunningham JJ, Brown JS, Gatenby RA, et al. Optimal control to develop therapeutic strategies  
595 for metastatic castrate resistant prostate cancer. *J Theor Biol*. 2018;459:67-78.

- 596 23. Ribba B, Boetsch C, Nayak T, et al. Prediction of the Optimal Dosing Regimen Using a  
597 Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy. *Clin Cancer*  
598 *Res.* 2018;24(14):3325-33.
- 599 24. Knight-Schrijver VR, Chelliah V, Cucurull-Sanchez L, et al. The promises of quantitative systems  
600 pharmacology modelling for drug development. *Comput Struct Biotechnol J.* 2016;14:363-70.
- 601 25. Fassoni AC, Baldow C, Roeder I, et al. Reduced tyrosine kinase inhibitor dose is predicted to be  
602 as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial  
603 data. *Haematologica.* 2018;103(11):1825-34.
- 604 26. Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor therapy  
605 before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a  
606 non-randomised, phase 2 trial. *Lancet Haematol.* 2019;6(7):e375-e83.
- 607 27. Mendelsohn ML. Cell proliferation and tumor growth. *Oxford: Blackwell Scientific Publications.*  
608 1963.
- 609 28. Borghans JA, de Boer RJ, Segel LA. Extending the quasi-steady state approximation by changing  
610 variables. *Bull Math Biol.* 1996;58(1):43-63.
- 611 29. Gadhamsetty S, Maree AF, Beltman JB, et al. A general functional response of cytotoxic T  
612 lymphocyte-mediated killing of target cells. *Biophys J.* 2014;106(8):1780-91.
- 613 30. McDonagh M, Bell EB. The survival and turnover of mature and immature CD8 T cells.  
614 *Immunology.* 1995;84(4):514-20.
- 615 31. Jenkins MK, Chu HH, McLachlan JB, et al. On the composition of the preimmune repertoire of  
616 T cells specific for Peptide-major histocompatibility complex ligands. *Annu Rev Immunol.* 2010;28:275-  
617 94.
- 618 32. Coulie PG, Karanikas V, Lurquin C, et al. Cytolytic T-cell responses of cancer patients vaccinated  
619 with a MAGE antigen. *Immunol Rev.* 2002;188:33-42.
- 620 33. Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human  
621 body. *Clin Investig.* 1992;70(7):539-44.
- 622 34. Ferrer R. Lymphadenopathy: differential diagnosis and evaluation. *Am Fam Physician.*  
623 1998;58(6):1313-20.
- 624 35. Vallini V, Ortori S, Boraschi P, et al. Staging of pelvic lymph nodes in patients with prostate  
625 cancer: Usefulness of multiple b value SE-EPI diffusion-weighted imaging on a 3.0 T MR system. *Eur J*  
626 *Radiol Open.* 2016;3:16-21.
- 627 36. Linderman JJ, Riggs T, Pande M, et al. Characterizing the dynamics of CD4+ T cell priming within  
628 a lymph node. *J Immunol.* 2010;184(6):2873-85.
- 629 37. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. *Adv Immunol.*  
630 2006;90:51-81.
- 631 38. Halle S, Halle O, Forster R. Mechanisms and Dynamics of T Cell-Mediated Cytotoxicity In Vivo.  
632 *Trends Immunol.* 2017;38(6):432-43.
- 633 39. Beck RJ, Slagter M, Beltman JB. Contact-Dependent Killing by Cytotoxic T Lymphocytes Is  
634 Insufficient for EL4 Tumor Regression In Vivo. *Cancer Res.* 2019;79(13):3406-16.
- 635 40. Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue? *Cell Cycle.*  
636 2009;8(3):505-6.
- 637 41. Moreno CC, Mittal PK, Sullivan PS, et al. Colorectal Cancer Initial Diagnosis: Screening  
638 Colonoscopy, Diagnostic Colonoscopy, or Emergent Surgery, and Tumor Stage and Size at Initial  
639 Presentation. *Clin Colorectal Cancer.* 2016;15(1):67-73.
- 640 42. Zastrow S, Phuong A, von Bar I, et al. Primary tumor size in renal cell cancer in relation to the  
641 occurrence of synchronous metastatic disease. *Urol Int.* 2014;92(4):462-7.
- 642 43. Ball DL, Fisher RJ, Burmeister BH, et al. The complex relationship between lung tumor volume  
643 and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a  
644 prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group  
645 (TROG 99.05). *Radiother Oncol.* 2013;106(3):305-11.



- 646 44. Vasaturo A, Halilovic A, Bol KF, et al. T-cell Landscape in a Primary Melanoma Predicts the  
647 Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. *Cancer*  
648 *Res.* 2016;76(12):3496-506.
- 649 45. Ahnert K, Mulansky M. Odeint – Solving Ordinary Differential Equations in C++. *AIP Conference*  
650 *Proceedings.* 2011;1389.
- 651 46. Scheffer M, Carpenter SR, Lenton TM, et al. Anticipating critical transitions. *Science.*  
652 2012;338(6105):344-8.
- 653 47. Scheffer M, Bascompte J, Brock WA, et al. Early-warning signals for critical transitions. *Nature.*  
654 2009;461(7260):53-9.
- 655 48. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:  
656 revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45(2):228-47.
- 657 49. Champiat S, Derclé L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of  
658 Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. *Clin Cancer Res.* 2017;23(8):1920-8.
- 659 50. Lesterhuis WJ, Bosco A, Millward MJ, et al. Dynamic versus static biomarkers in cancer immune  
660 checkpoint blockade: unravelling complexity. *Nat Rev Drug Discov.* 2017;16(4):264-72.
- 661 51. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host  
662 immune system and tumor immunotherapy by PD-L1 blockade. *Proc Natl Acad Sci U S A.*  
663 2002;99(19):12293-7.
- 664 52. Yang B, Li M, Tang W, et al. Dynamic network biomarker indicates pulmonary metastasis at the  
665 tipping point of hepatocellular carcinoma. *Nat Commun.* 2018;9(1):678.
- 666 53. Liu R, Wang J, Ukai M, et al. Hunt for the tipping point during endocrine resistance process in  
667 breast cancer by dynamic network biomarkers. *J Mol Cell Biol.* 2019;11(8):649-64.
- 668 54. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. *Curr Opin Pharmacol.* 2015;23:32-8.
- 669 55. Thomas A, Routh ED, Pullikuth A, et al. Tumor mutational burden is a determinant of immune-  
670 mediated survival in breast cancer. *Oncoimmunology.* 2018;7(10):e1490854.
- 671 56. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-  
672 ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm,  
673 multicentre, phase 2 trial. *Lancet.* 2017;389(10064):67-76.
- 674 57. Blank CU, Haanen JB, Ribas A, et al. CANCER IMMUNOLOGY. The "cancer immunogram".  
675 *Science.* 2016;352(6286):658-60.
- 676 58. Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the  
677 classification of cancer. *J Transl Med.* 2012;10:1.
- 678

## 679 LIST OF ABBREVIATIONS

680 BIC: Bayesian Information Criterion; ICI: Immune Checkpoint Inhibition; LDH: Lactate dehydrogenase;  
681 ODE: Ordinary Differential Equation; PD-(L)1: Programmed Death-(Ligand) 1; TMB: Tumor Mutational  
682 Burden.

683

## 684 DECLARATIONS

### 685 Ethics approval and consent to participate

686 Not applicable.

687

### 688 Consent for publication

689 Not applicable.

690



691 **Availability of data and material**

692 The code of the ODE model is available at GitHub: [https://github.com/jeroencreemers/tipping-point-](https://github.com/jeroencreemers/tipping-point-cancer-immune-dynamics)  
693 [cancer-immune-dynamics](https://github.com/jeroencreemers/tipping-point-cancer-immune-dynamics).

694

695 **Competing interests**

696 WJL reports consultancy activities for Douglas Pharmaceuticals and MSD; research funding from  
697 Douglas Pharmaceuticals, AstraZeneca, and ENA therapeutics; patents PCT/AU2019/050259 and  
698 PCT/AU2015/000458 (all outside this work). NM reports personal fees from Bayer and Merck Sharp &  
699 Dohme; grants and personal fees from Jansen-Cilag, Roche, Astellas, and Sanofi (all outside this work).  
700 WRG reports consultancy activities for Bristol-Myers Squibb, IMS Health, Janssen-Cilag, Sanofi, and  
701 MSD; speaker fees from ESMO and MSD; and research funding from Bayer, Astellas, Janssen-Cilag, and  
702 Sanofi (all outside this work).

703

704 **Funding**

705 JC was funded by the Radboudumc. WJL was supported by Fellowships from the NHMRC, the Simon  
706 Lee Foundation, and the Cancer Council Western Australia. CF received an ERC Adv Grant ARTimmune  
707 (834618) and an NWO Spinoza grant. IV received an NWO-Vici grant (918.14.655). JT was supported  
708 by a Young Investigator Grant (10620) from the Dutch Cancer Society and an NWO grant  
709 (VI.Vidi.192.084).

710

711 **Authors' contribution**

712 JHAC and JT conceived this study. JHAC performed the experiments and wrote the manuscript under  
713 the supervision of JT. All authors provided feedback on the manuscript and reviewed the manuscript  
714 prior to submission.

715

716 **Acknowledgments**

717 Not applicable.